Table 3 Respiratory support, specific treatment modalities and complications

Ventilatory support

 Self-proning, n (%)

3 (3)

1 (2)

2 (3)

1.0

 High-flow, n (%)

36 (31)

15 (26)

21 (36)

0.3

 Duration of high-flow, days

2.3 ± 1.6

2.3 ± 2.1

2.2 ± 1.2

0.9

 NIV, n (%)

39 (34)

17 (29)

22 (37)

0.5

 Duration of NIV, days

2.5 ± 2.1

1.5 ± 0.8

3.2 ± 2.5

0.01^a

 IMV, n (%)

75 (65)

27 (47)

48 (81)

0.001^a

 Duration of IMV, days

10.3 ± 8.7

8.0 ± 8.5

11.5 ± 8.6

0.09

 Proning during IMV, n (%)

12 (10)

2 (3)

10 (17)

0.04^a

 Maximal PEEP, cmH₂O

12 ± 4

11 ± 4

12 ± 3

0.2

 Tidal volume, ml

536 ± 110

560 ± 93

525 ± 117

0.3

 Highest Peak pressure, cmH₂O

36 ± 7

32 ± 7

37 ± 6

0.01^a

Medical and renal support

 Methylprednisolone, n (%)

117 (100)

58 (100)

59 (100)

1,0

 Levosimendan, n (%)

8 (7)

5 (9)

3 (5)

0.4

 Nitric oxide inhalation, n (%)

2 (2)

2 (4)

0

0.3

 Thrombolysis (rTPA), n (%)

3 (3)

1 (2)

2 (4)

0.5

 Renal replacement therapy, n (%)

18 (16)

4 (7)

14 (24)

0.012^a

Complication rate:

 VAP, n (%)

41 (35)

12 (21)

29 (49)

0.001

 CRBSI, n (%)

1 (1)

0

1 (2)

0.5

 Urosepsis, n (%)

24 (21)

12 (21)

12 (10)

0.6

 Fungal infection, n (%)

35 (29)

13 (22)

21 (36)

0.09